Craig L. Slingluff, Jr., MD
University of Virginia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Craig L. Slingluff, Jr., MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:48 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05839912 · Excision of Lymph Node Trial (EXCILYNT) (Mel69)Craig L Slingluff, Jr · recruiting · Melanoma
- Ph1/Ph2NCT04364230 · Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)Craig L Slingluff, Jr · completed · Melanoma, Ocular Melanoma, Uveal Melanoma · principal investigator
- Ph1/Ph2NCT03617328 · Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV MelanomaCraig L Slingluff, Jr · completed · Melanoma
- Ph1/Ph2NCT02643303 · A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer Research · completed · Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma
- Ph1/Ph2NCT02515227 · Safety Study of a Helper Peptide Vaccine Plus PembrolizumabCraig L Slingluff, Jr · completed · Melanoma · study director
- Ph1/Ph2NCT02425306 · Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of MelanomaCraig L Slingluff, Jr · terminated · Melanoma · principal investigator
- Ph1/Ph2NCT02385669 · A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With MelanomaCraig L Slingluff, Jr · terminated · Melanoma · study director
- Early Ph1NCT02382549 · A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibCraig L Slingluff, Jr · terminated · Melanoma · study director
- Ph1NCT01846143 · Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced MalignanciesCraig L Slingluff, Jr · completed · Melanoma · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIESR01CA178846 · NCI · UNIVERSITY OF VIRGINIA · PI Craig Lee Slingluff · fiscal years 2015 to 2017Named on NCT02515227, NCT02382549
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.